Maternal and fetal outcomes of spinal cord stimulation in pregnancy: systematic review with descriptive meta-analysis.

J Clin NeurosciJun 3, 2026 (epub)
Clinical ResearchAnesthesiologyObstetrics & Gynecology

Barbara Buccilli, Nuha Mohammed, Dina Mohammed et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis evaluated maternal and fetal outcomes in 31 pregnant patients with spinal cord stimulation (SCS) devices. The study found that SCS is well tolerated during pregnancy, with low device-related complications and favorable maternal and neonatal outcomes, including term deliveries and normal birthweights.

Key findings

  • Device-related complications were uncommon, with no infections or explantations reported.
  • Most pregnancies maintained effective stimulation with infrequent reprogramming.
  • Term delivery predominated, with normal birthweights and favorable Apgar scores.

Why it matters

Understanding the safety of spinal cord stimulation during pregnancy is crucial for managing pain in women of reproductive age. This evidence supports the continued use of SCS in this population, ensuring both maternal and fetal well-being.

Source

PubMed · PMID 42235384

Published in J Clin Neurosci. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Anesthesiology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.